文献速递临床试验与 GCP

评估健康个体中不同COVID-19疫苗组合安全性和免疫原性的随机、受试者盲法、对照3期试验研究方案(PRIBIVAC)

Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
PubMed 文献 · Trials · 2022-06-16

该3期随机受试者盲法对照试验计划在最多600名已完成两剂同源mRNA疫苗基础免疫至少6个月的成人中,比较异源加强(干预组1-4)与同源加强(对照组)的安全性和免疫原性。主要终点为加强后第28天抗SARS-CoV-2刺突免疫球蛋白水平,针对野生型及关注变异株检测,并全面分析体液和细胞免疫应答。

要点

  • 研究对象为完成两剂同源mRNA疫苗基础免疫至少6个月的成人,排除既往SARS或SARS-CoV-2感染、免疫抑制或妊娠者。
  • 干预组为异源加强方案(1-4组),对照组为同源加强,随机等概率分配至当时可用的干预组。
  • 主要终点为加强后第28天抗SARS-CoV-2刺突免疫球蛋白水平,针对野生型和关注变异株检测。

核心结论

  • 该研究将提供数据以理解同源和异源第三剂COVID-19疫苗加强免疫应答的数量、质量和持久性,是发展基础免疫系列之后COVID-19疫苗接种规划的重要一步。

研究设计与样本

  • 3期、随机、受试者盲法、对照临床试验,计划纳入最多600名成人志愿者。
  • 受试者需已完成两剂同源mRNA疫苗(BNT162b2或mRNA-1273)基础免疫至少6个月。
  • 随机等概率分配至随机时点可用的干预组(异源加强1-4组)或对照组(同源加强)。
  • 排除有确诊SARS或SARS-CoV-2感染史、免疫抑制或妊娠者。
  • 通过体格检查、实验室检查和自我报告监测不良事件和严重不良事件,并在接种前/筛查(第-14天至第0天)、第7天、第28天、第180天、第360天采集血样。

主要发现

  • 该文为研究方案,未报告试验结果。

关键数值与推荐

  • 主要终点为加强后第28天抗SARS-CoV-2刺突免疫球蛋白水平,针对野生型SARS-CoV-2和关注变异株检测。
  • 将对疫苗接种的体液和细胞免疫应答进行全面免疫分析。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Programme for use as the primary vaccination series. More than 90% of the Singapore population has received at least one dose of a COVID-19 vaccine as of December 2021. With the demonstration that vaccine effectiveness wanes in the months after vaccination, and the emergence of Omicron which evades host immunity from prior infection and/or vaccination, attention in many countries has shifted to how best to maintain immunity through booster vaccinations. METHODS: The objectives of this phase 3, randomized, subject-blinded, controlled clinical trial are to assess the safety and immunogenicity of heterologous boost COVID-19 vaccine regimens (intervention groups 1-4) compared with a homologous boost regimen (control arm) in up to 600 adult volunteers. As non-mRNA vaccine candidates may enter the study at different time points depending on vaccine availability and local regulatory approval, participants will be randomized at equal probability to the available intervention arms at the time of randomization. Eligible participants will have received two doses of a homologous mRNA vaccine series with BNT162b2 or mRNA-1273 at least 6 months prior to enrolment. Participants will be excluded if they have a history of confirmed SARS or SARS-CoV-2 infection, are immunocompromised, or are pregnant. Participants will be monitored for adverse events and serious adverse events by physical examinations, laboratory tests and self-reporting. Blood samples will be collected at serial time points [pre-vaccination/screening (day - 14 to day 0), day 7, day 28, day 180, day 360 post-vaccination] for assessment of antibody and cellular immune parameters. Primary endpoint is the level of anti-SARS-CoV-2 spike immunoglobulins at day 28 post-booster and will be measured against wildtype SARS-CoV-2 and variants of concern. Comprehensive immune profiling of the humoral and cellular immune response to vaccination will be performed. DISCUSSION: This study will provide necessary data to understand the quantity, quality, and persistence of the immune response to a homologous and heterologous third booster dose of COVID-19 vaccines. This is an important step in developing COVID-19 vaccination programs beyond the primary series. TRIAL REGISTRATION: ClinicalTrials.gov NCT05142319 . Registered on 2 Dec 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Poh XY, Lee IR, Lim C, et al. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]. Trials. 2022. PMID: 35710572. doi:10.1186/s13063-022-06345-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。